DDInter1607 DDInter462
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Ritonavir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inducers
Cytochrome P450 2C19 Inducers {u} (Pharmacologic Class) includes {v} (Compound) Dabrafenib
Ritonavir {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Ritonavir {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) regulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Ritonavir {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is regulated by {v} (Gene) SIK1
SIK1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Ritonavir {u} (Compound) binds {v} (Gene) SLCO1B1
SLCO1B1 {u} (Gene) covaries with {v} (Gene) DHRS1
DHRS1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inducers
Cytochrome P450 2C19 Inducers {u} (Pharmacologic Class) includes {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Ritonavir {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Ritonavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Ritonavir (Compound) is included by Cytochrome P450 2C19 Inducers (Pharmacologic Class) and Cytochrome P450 2C19 Inducers (Pharmacologic Class) includes Dabrafenib (Compound)
Ritonavir (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Ritonavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) regulates ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)
Ritonavir (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is regulated by SIK1 (Gene) and SIK1 (Gene) is bound by Dabrafenib (Compound)
Ritonavir (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Ritonavir (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) covaries with DHRS1 (Gene) and DHRS1 (Gene) is upregulated by Dabrafenib (Compound)
Ritonavir (Compound) is included by Cytochrome P450 2C19 Inducers (Pharmacologic Class) and Cytochrome P450 2C19 Inducers (Pharmacologic Class) includes Enzalutamide (Compound) and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Ritonavir (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib